NATCOPHARM
Natco Pharma Limited (NATCOPHARM) Stock Analysis
Natco Pharma Limited is an Indian pharmaceutical company known for complex generics, oncology, and niche therapies including hepatitis and cancer treatments. It challenges patents with first-to-file strategies in regulated markets. Manufacturing and R&D capabilities support global filings. It is listed on Indian stock exchanges.
Healthcare › Drug Manufacturers - Specialty & Generic
₹782.60
-3.39% 1W | -3.80% 52W
Market Cap
14.4k CR
P/E Ratio
12.4
52W High
₹1226.8
52W Low
₹781
Div. Yield
0.75%
Beta
0.1
50 DMA
₹847.3
200 DMA
₹939.4
Profit Margin
32.8%
Inst. Own.
13%
📊 CONSOLIDATION
⚠️ BREAKDOWN
Fundamentals
Profit & Loss
| Metric | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1,140 | 1,031 | 759 | 1,068 | 1,363 | 1,371 | 475 | 1,221 | 1,329 | 1,363 | 647 | 739 | 735 |
| Expenses | 612 | 573 | 490 | 571 | 558 | 567 | 436 | 673 | 758 | 784 | 489 | 612 | 549 |
| Operating Profit | 528 | 458 | 268 | 497 | 805 | 804 | 39 | 548 | 571 | 579 | 159 | 128 | 186 |
| OPM % | 46% | 44% | 35% | 47% | 59% | 59% | 8% | 45% | 43% | 42% | 25% | 17% | 25% |
| Other Income | 20 | 29 | 37 | 42 | 48 | 64 | 176 | 66 | 62 | 100 | 58 | 78 | 59 |
| Interest | 4 | 4 | 5 | 6 | 5 | 4 | 4 | 10 | 3 | 13 | 10 | 11 | 13 |
| Depreciation | 44 | 44 | 44 | 56 | 44 | 46 | 47 | 98 | 58 | 52 | 46 | 50 | 47 |
| Profit before tax | 500 | 440 | 256 | 478 | 804 | 818 | 164 | 506 | 572 | 614 | 161 | 144 | 186 |
| Tax % | 16% | 16% | 17% | 19% | 17% | 17% | 19% | 20% | 16% | 16% | 13% | -62% | 34% |
| Net Profit | 420 | 369 | 213 | 386 | 668 | 676 | 132 | 406 | 480 | 518 | 151 | 269 | 206 |
| EPS in Rs | 21.42 | 18.81 | 10.84 | 19.69 | 34.07 | 34.52 | 6.78 | 20.72 | 24.50 | 26.42 | 7.72 | 13.65 | 10.52 |
| Metric | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 825 | 1,042 | 2,020 | 2,185 | 2,094 | 1,915 | 2,052 | 1,945 | 2,707 | 3,999 | 4,430 | 4,078 | 3,485 |
| Expenses | 615 | 777 | 1,337 | 1,256 | 1,300 | 1,332 | 1,446 | 1,681 | 1,772 | 2,245 | 2,234 | 2,617 | 2,433 |
| Operating Profit | 210 | 266 | 683 | 928 | 795 | 583 | 606 | 264 | 936 | 1,754 | 2,196 | 1,462 | 1,052 |
| OPM % | 25% | 25% | 34% | 42% | 38% | 30% | 30% | 14% | 35% | 44% | 50% | 36% | 30% |
| Other Income | 0 | 12 | 14 | 40 | 130 | 107 | 104 | 99 | 105 | 126 | 354 | 272 | 295 |
| Interest | 32 | 23 | 18 | 15 | 19 | 22 | 13 | 18 | 14 | 19 | 24 | 37 | 46 |
| Depreciation | 47 | 51 | 54 | 66 | 81 | 100 | 117 | 143 | 164 | 187 | 235 | 207 | 196 |
| Profit before tax | 132 | 204 | 624 | 887 | 825 | 569 | 580 | 202 | 862 | 1,674 | 2,291 | 1,491 | 1,104 |
| Tax % | 1% | 24% | 22% | 22% | 22% | 19% | 24% | 16% | 17% | 17% | 18% | 8% | |
| Net Profit | 130 | 156 | 485 | 695 | 642 | 458 | 442 | 170 | 715 | 1,388 | 1,883 | 1,418 | 1,145 |
| EPS in Rs | 7.40 | 8.23 | 25.46 | 34.45 | 32.17 | 23.11 | 22.08 | 8.50 | 35.78 | 70.76 | 96.10 | 72.30 | 58.31 |
| Dividend Payout % | 12% | 14% | 24% | 22% | 18% | 27% | 22% | 48% | 14% | 12% | 6% | 6% |
Growth — CAGR
| Metric | 3Y | 5Y | 10Y |
|---|---|---|---|
| Revenue CAGR | 15.0% | 15.0% | 15.0% |
| Profit CAGR | 27.0% | 28.0% | 25.0% |
Shareholding Pattern
Promoters49.56%
FIIs15.52%
DIIs5.81%
Public29.12%
Promoters49.48%
FIIs14.09%
DIIs5.87%
Public30.56%
Promoters49.48%
FIIs15.16%
DIIs5.39%
Public29.97%
Promoters49.41%
FIIs17.37%
DIIs5.46%
Public27.74%
Promoters49.41%
FIIs16.99%
DIIs5.63%
Public27.97%
Promoters48.84%
FIIs11.91%
DIIs15.38%
Public23.87%
Promoters49.71%
FIIs16.14%
DIIs9.69%
Public24.46%
Promoters49.56%
FIIs17.49%
DIIs5.64%
Public27.30%
Promoters49.41%
FIIs17.37%
DIIs5.46%
Public27.74%
Promoters49.41%
FIIs16.99%
DIIs5.63%
Public27.97%
NATCOPHARM
Holdings Analysis
Key strengths & risk signals
66
Overall
81
Fundamental
51
Technical
Risks (4)
NEGLIGIBLE DIVIDEND! 0.74% yield - little to no income.
WEAK POSITION! Current price (789.1) is below both moving averages.
WEAK! Trading at 0.4% of 52W range - near yearly lows.
NEGATIVE MOMENTUM! Price declined across timeframes - down 4.2% (1 week), 3.2% (1 month), 18.6% (3 months).
Strengths (4)
EXCELLENT EFFICIENCY! 32.8% profit margin - company keeps strong profits.
LOW VOLATILITY! Beta of 0.10 - stable stock, less market risk.
APPROACHING OVERSOLD! RSI at 33.9 - watch for reversal.
BULLISH SENTIMENT! In last 30 days: 13 up days, 17 down days. Avg volume on up days: 471,797 vs down days: 415,949. Ratio: 1.13x
Fundamental & Technical Analysis
66Overall
81Fundamental
51Technical
Fundamental Breakdown
Growth Quality
26/30
Revenue CAGR: 14.5% (GOOD, 11/15). Profit CAGR: 25.6% (EXCELLENT, 15/15).
Profit Margin
10/10
EXCELLENT EFFICIENCY! 32.8% profit margin - company keeps strong profits.
PEG Valuation
10/10
UNDERVALUED! PEG of 0.48 indicates stock is cheap relative to growth.
Dividend Yield
3/10
NEGLIGIBLE DIVIDEND! 0.75% yield - little to no income.
Debt to Equity
10/10
VERY LOW DEBT! D/E of 0.00 - excellent financial health.
Public Holding
14/20
MODERATE PUBLIC HOLDING! 24.08% public ownership - balanced ownership structure.
Stability Index
8/10
GOOD STABILITY! Only 1 revenue dip in history. Strong business fundamentals.
Technical Breakdown
Moving Averages
5/10
BEARISH TREND! 50-day average (847.3) is below 200-day average (939.4) - negative signal.
Price Position
2/10
WEAK POSITION! Current price (782.6) is below both moving averages.
Trend Pattern
10/20
BREAKDOWN! Stock has broken below support levels - weakness present.
52W Performance
3/10
WEAK YEAR! Stock declined 3.8% in the last year.
Volume Sentiment
20/30
BULLISH SENTIMENT! In last 30 days: 13 up days, 17 down days. Avg volume on up days: 471,797 vs down days: 419,029. Ratio: 1.13x
RSI
4/5
APPROACHING OVERSOLD! RSI at 32.1 - watch for reversal.
52W Range
1/5
WEAK! Trading at 0.4% of 52W range - near yearly lows.
Momentum
1/5
NEGATIVE MOMENTUM! Price declined across timeframes - down 3.4% (1 week), 4.0% (1 month), 19.0% (3 months).
Beta
5/5
LOW VOLATILITY! Beta of 0.10 - stable stock, less market risk.
NATCOPHARM
Concall / Investor Presentation
Earnings call transcripts & AI summaries
| Quarter | Concall | Summary |
|---|---|---|
| Q4FY262026-06-04 | Concall PDF | |
| Q3FY262026-02-18 | Concall PDF | |
| Q2FY262025-11-20 | Concall PDF |
Peer Comparison
Healthcare · Drug Manufacturers - Specialty & Generic · 8 stocks
| Stock | Price | P/E | Profit Margin | Revenue CAGR 5Y | Profit CAGR 5Y | 52W Change | Stock Strength | Trendline | YoY Profit | QoQ Profit | YoY Revenue | QoQ Revenue |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| NATCOPHARM | ₹782.60 | 12.4 | 32.8% | 14.5% | 25.6% | -3.8% | 66 | BREAKDOWN | -57.0% | -22.9% | -44.7% | -0.5% |
| JUBLPHARMA | ₹938.90 | 42.4 | 4.1% | 9.8% | – | -12.4% | 54 | BREAKDOWN | -45.1% | -52.7% | +18.2% | -2.2% |
| ASTRAZEN | ₹5,950.50 | 87.7 | 7.0% | 31.3% | 23.6% | -35.3% | 56 | APPROACHING SUPPORT | -32.1% | -15.6% | +29.7% | +18.0% |
| APLLTD | ₹792.50 | 22.7 | 8.9% | 9.5% | 25.4% | -14.0% | 74 | CONSOLIDATING UP | +12.1% | -14.6% | +25.7% | +16.4% |
| ERIS | ₹1,149.60 | 24.5 | 20.0% | 23.3% | 17.5% | -27.0% | 64 | BREAKDOWN | +20.7% | -49.4% | +12.6% | +15.5% |
| ALIVUS | ₹1,348.00 | 27.5 | 23.3% | 6.9% | 6.5% | +44.0% | 70 | APPROACHING RESISTANCE | +31.8% | -1.6% | +6.4% | -7.1% |
| SUDEEPPHRM | ₹1,055.20 | 64.7 | 27.0% | 14.4% | 40.5% | +30.7% | 73 | BREAKDOWN | +31.8% | -17.0% | +26.7% | -13.2% |
| AKUMS | ₹770.00 | 41.4 | 6.5% | 7.0% | 39.1% | +62.1% | 76 | BREAKDOWN | +57.5% | +18.2% | +13.9% | +0.8% |
Data from TradeAlone · Updated daily
NATCOPHARM News
Natco Pharma Limited (NATCOPHARM) moves down 6% intraday2026-08-14Natco Pharma Limited Receives Tentative Approval for Olaparib Tablets from U.S. FDA2026-07-18Natco Pharma Limited (NSE: Natcopharm) Completes Acquisition of Additional 13.25% Stake in Adcock Ingram2026-07-14Natco Pharma Limited (NSE: NATCOPHARM) gains 5% intraday2026-07-07Natco Pharma Limited (NSE: NATCO Pharm) Receives FDA Approval for Eribulin Mesylate Injection2026-06-03
